| 7.29 0 (0%) | 05-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.63 | 1-year : | 8.77 |
| Resists | First : | 7.39 | Second : | 7.51 |
| Pivot price | 7.31 | |||
| Supports | First : | 7.21 | Second : | 5.99 |
| MAs | MA(5) : | 7.33  |
MA(20) : | 7.32 |
| MA(100) : | 6.71 |
MA(250) : | 5.51 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 47.8 |
| RSI | RSI(14): 52.5 | |||
| 52-week | High : | 7.55 | Low : | 3.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KZR ] has closed above bottom band by 30.4%. Bollinger Bands are 77.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.48 - 7.53 | 7.53 - 7.56 |
| Low: | 7.16 - 7.22 | 7.22 - 7.26 |
| Close: | 7.21 - 7.3 | 7.3 - 7.36 |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Thu, 28 May 2026
Baselake files Schedule 13G/A reporting 0 shares in Kezar Life Sciences (KZR) - Stock Titan
Thu, 14 May 2026
[EFFECT] Kezar Life Sciences, Inc. SEC Filing - Stock Titan
Wed, 13 May 2026
Aurinia deal leaves Kezar (KZR) wholly owned as Tang Capital exits - Stock Titan
Tue, 12 May 2026
Baselake amends Schedule 13G for Kezar Life Sciences (NASDAQ: KZR) - Stock Titan
Mon, 11 May 2026
Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results - MarketBeat
Mon, 11 May 2026
Kezar Life Sciences acquired by Aurinia Pharma U.S.; Nasdaq delisting follows - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 152 (K) |
| Shares Short P.Month | 192 (K) |
| EPS | -6.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.56 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.6 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.57 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|